A global registry of women affected by COVID-19 in pregnancy, understanding natural history to guide treatment and prevention

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:5 publications

Grant number: MC_PC_19066

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $313,278.91
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Imperial College London
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Newborns (birth to 1 month)Unspecified

  • Vulnerable Population

    Pregnant women

  • Occupations of Interest

    Unspecified

Abstract

This COVID-19 Rapid Response award is jointly funded (50:50) between the Medical Research Council and the National Institute for Health Research. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project. BACKGROUND. In the current COVID outbreak, there are case reports with variable outcomes reported for 18 women affected by nCoV in the third trimester, 50% delivered pre-term but there were no reports of vertical transmission. Therefore there are significant knowledgegaps regarding the impact of COVID-19 on mothers' and babies' health at all stages of pregnancy, including delivery and neonatal care, due to lack of primary data. SARS and MERS resulted in >25% case fatality in pregnant women, with worse effects in those infected in earlier pregnancy. AIMS To understand the natural history of COVID-19 in pregnancy, in order to guide treament and prevention during the outbreak. DELIVERABLES Registry: We will construct a registry of women affected by COVID-19 during pregnancy, detailing presenting symptoms, clinical course, key diagnostic testing modalities and pathology results, adverse pregnancy outcomes, including vertical transmission, perinatal and neonatal outcomes. Pseudonymised data will be entered by health professionals via a password-protected web portal; the database will be hosted in an established clinical trials unitwith a study co-ordinator, senior data manager and statistician. We have a network of collaborators across Europe, China and USA to identify cases from these areas. Our senior project-partners in China and Hong Kong have expertise in women and children's health and epidemiology and will facilitate case reporting in areas which have a high prevalence of COVID-19 . This registry will be used to produce weekly online reports of aggregated, anonymised data during the outbreak to inform treatment and prevention during the outbreak, within the period of the grant. Data sharing (for pseudonymised individual participant data) will be made available for ethically approved research during and after the outbreak.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Clinical risk factors of adverse outcomes among women with COVID-19 in the pregnancy and postpartum period: a sequential, prospective meta-analysis.

Protocol for a sequential, prospective meta-analysis to describe coronavirus disease 2019 (COVID-19) in the pregnancy and postpartum periods.

Pregnancy and neonatal outcomes of COVID-19: The PAN-COVID study.

Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries.

Pregnancy and neonatal outcomes in COVID-19: study protocol for a global registry of women with suspected or confirmed SARS-CoV-2 infection in pregnancy and their neonates, understanding natural history to guide treatment and prevention.